Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: A plausible therapeutic approach in Alzheimer's disease

Medical Hypotheses

Volumn 83, Issue 1, 2014, Pages 39-46

  Khalid, Shumaila ^a   Paul, Subhankar ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; HEAT SHOCK PROTEIN 90 INHIBITOR; LEUCINE; NOVOBIOCIN; TAU PROTEIN; HEAT SHOCK PROTEIN 90;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COMPUTER MODEL; DRUG BINDING SITE; GENETIC ALGORITHM; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; NUCLEOTIDE BINDING SITE; PROTEIN DEGRADATION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; COMPUTER SIMULATION; HUMAN; METABOLISM;

ADENOSINE TRIPHOSPHATE; ALZHEIMER DISEASE; BINDING SITES; COMPUTER SIMULATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS;

EID: 84901064782     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.04.013     Document Type: Article

References (43)

1. Tiraboschi P., Hansen L.A., Thal L.J., Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004, 62:1984-1989.
2. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
3. Billingsley M.L., Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997, 323:577-591.
4. Goedert M., Spillantini M.G., Crowther R.A. Tau proteins and neurofibrillary degeneration. Brain Pathol 1991, 1:279-286.
5. Chun W., Johnson G.V. The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci 2007, 12:733-756.
6. Kosik K.S., Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim Biophys Acta 2005, 1739:298-310.
7. Shimura H., Schwartz D., Gygi S.P., Kosik K.S. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 2004, 279:4869-4876.
8. Jiang J., Ballinger C.A., Wu Y., Dai Q., Cyr D.M., Hohfeld J., et al. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem 2001, 276:42938-42944.
9. Concannon C.G., Gorman A.M., Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis 2003, 8:61-70.
10. Salminen A., Ojala J., Kaarniranta K., Hiltunen M., Soininen H. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease. Prog Neurobiol 2011, 93:99-110.
11. Jinwal U.K., Trotter J.H., Abisambra J.F., Koren J., Lawson L.Y., Vestal G.D., et al. The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. J Biol Chem 2011, 286:16976-16983.
12. Garnier C., Barbier P., Devred F., Rivas G., Peyrot V. Hydrodynamic properties and quaternary structure of the 90 kDa heat-shock protein: effects of divalent cations. Biochemistry 2002, 41:11770-11778.
13. Prodromou C., Panaretou B., Chohan S., Siligardi G., O'Brien R., Ladbury J.E., et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J 2000, 19:4383-4392.
14. Wayne N., Bolon D.N. Dimerization of Hsp90 is required for in vivo function. Design and analysis of monomers and dimers. J Biol Chem 2007, 282:35386-35395.
15. Supko J.G., Hickman R.L., Grever M.R., Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995, 36:305-315.
16. Schulte T.W., Neckers L.M. The benzoquinoneansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998, 42:273-279.
17. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water soluble inhibitors of Hsp90. J Med Chem 2006, 49:4606-4615.
18. Glaze E.R., Lambert A.L., Smith A.C., Page J.G., Johnson W.D., McCormick D.L., et al. Preclinical toxicity of a geldanamycinanalog, 17-(dimethylaminoethylamino)- 17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 2005, 56:637-647.
19. Egorin M.J., Rosen D.M., Wolff J.H., Callery P.S., Musser S.M., Eiseman J.L. Metabolism of 17-(allylamino)- 7-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998, 58:2385-2396.
20. Palermo C.M., Westlake C.A., Gasiewicz T.A. Epigallocatechingallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry 2005, 44:5041-5052.
21. Marcu M.G., Schulte T.W., Neekers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 2000, 92:242-248.
22. Palermo C.M., Hernando J.I., Dertinger S.D., Kende A.S., Gasiewicz T.A. Identification of potential aryl hydrocarbon receptor antagonists in green tea. Chem Res Toxicol 2003, 16:865-872.
23. East A.J., Ollis W.D., Wheeler R.E. Natural occurrence of 3-aryl-4-hydroxycoumarins. Part I. Phytochemical examination of Derris robusta (roxb) benth. J Chem Soc 1969, 3:365-373.
24. Hadden M.K., Galam L., Gestwicki J.E., Matts R.L., Blagg B.S.J. Derrubone, an inhibitor of the Hsp90 protein folding machinery. J Nat Prod 2007, 70:2014-2018.
25. Marcu M.G., Chadli A., Bohouche I., Catelli B., Neekers L.M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 2001, 275:37181-37186.
26. Sgobba M., Forestiero R., Degliesposti G., Rastelli G. Exploring the binding site of C-terminal Hsp90 inhibitors. J Chem Inf Model 2010, 50:1522-1528.
27. Shiau A.K., Harris S.F., Southworth D.R., Agard D.A. Structural analysis of E. coli Hsp90 reveals dramatic nuclotide-dependent conformational rearrangements. Cell 2006, 127:329-340.
28. Matts R.L., Dixit A., Peterson L.B., Sun L. Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol 2011, 6:800-807.
29. Chauhan J.S., Mishra N.K., Raghava G.P.S. Identification of ATP binding residues of a protein from its primary sequence. BMC Bioinformatics 2009, 10:434.
30. Dou F., Netzer W.J., Tanemura K., Li F., Hartl F.U., Takashima A., et al. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A 2003, 100:721-726.
31. Ansar S., Burlison J.A., Hadden M.K., Yu X.M., Desino K.E., Bean J., et al. A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg Med Chem Lett 2007, 17:1984-1990.
32. Amolins M.W., Blagg B.S. Natural product inhibitors of Hsp90: potential leads for drug discovery. Mini Rev Med Chem 2009, 9:140-152.
33. Peterson L.B. Investigation of the Hsp90 C-terminal binding site, novel inhibitors and isoform-dependent client proteins 2012, Kansas University.
34. Allan R.K., Mok D., Ward B.K., Ratajczak T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J Biol Chem 2006, 281:7161-7171.
35. Yun B.G., Huang W., Leach N., Hartson S.D., Matts R.L. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 2004, 43:8217-8229.
36. Soti C., Racz A., Csermely P. A nucleotide-dependent molecular switch controls atp binding at the C-terminal domain of Hsp90. J Biol Chem 2001, 277:7066-7075.
37. Pratt W.B., Morishima Y., Peng H.M., Osawa Y. Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med (Maywood) 2010, 235:278-289.
38. Garnier C., Lafitte D., Tsvetkov P.O., Barbier P., Leclerc-Devin J., Millot J.M., et al. Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem 2002, 277:12208-12214.
39. Hastings J.M., Hadden M.K., Blagg B.S.J. Synthesis and evaluation of derrubone and select analogues. J Org Chem 2008, 73:369-373.
40. Csermely P., Kajtar J., Hollosi M., Jalsovszky G., Holly S., Kahn C.R., et al. ATP induces a conformational change of the 90-kDa heat shock protein (Hsp90). J Biol Chem 1993, 268:1901-1907.
41. Zou J., Guo Y., Guettouche T., Smith D.F., Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998, 94:471-480.
42. Brand J.G., Toribara T.Y. Equilibrium dialysis and circular dichroic analysis of the novobiocin bovine serum albumin complex. Arch Biochem Biophys 1976, 174:541-545.
43. Coulson C.J., Smith V.J. Correlation of hydrophobicity with protein binding for clorobiocin analogs. J Pharm Sci 1980, 69:799-801.